Shares of Elevation Oncology, Inc. (NASDAQ:ELEV - Get Free Report) have earned a consensus rating of "Buy" from the six ratings firms that are covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $7.40.
Several analysts have issued reports on ELEV shares. HC Wainwright restated a "buy" rating and set a $6.00 price target on shares of Elevation Oncology in a research report on Tuesday, April 9th. JMP Securities reaffirmed a "market outperform" rating and issued a $7.00 price target on shares of Elevation Oncology in a research note on Thursday, March 7th. Stephens assumed coverage on Elevation Oncology in a research note on Tuesday. They set an "overweight" rating and a $8.00 price objective for the company. Finally, Wedbush reaffirmed an "outperform" rating and issued a $8.00 target price on shares of Elevation Oncology in a research note on Friday, May 3rd.
Check Out Our Latest Stock Analysis on ELEV
Elevation Oncology Price Performance
Shares of NASDAQ ELEV traded up $0.02 during trading hours on Tuesday, reaching $3.56. 378,775 shares of the stock traded hands, compared to its average volume of 2,354,370. The company's 50-day simple moving average is $4.31 and its two-hundred day simple moving average is $2.54. The company has a market capitalization of $194.52 million, a P/E ratio of -3.63 and a beta of 1.52. Elevation Oncology has a 52-week low of $0.36 and a 52-week high of $5.89. The company has a quick ratio of 46.22, a current ratio of 46.22 and a debt-to-equity ratio of 0.41.
Elevation Oncology (NASDAQ:ELEV - Get Free Report) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.02. Equities research analysts forecast that Elevation Oncology will post -0.89 EPS for the current year.
Institutional Trading of Elevation Oncology
An institutional investor recently bought a new position in Elevation Oncology stock. SG Americas Securities LLC bought a new position in Elevation Oncology, Inc. (NASDAQ:ELEV - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The firm bought 12,244 shares of the company's stock, valued at approximately $63,000. 83.70% of the stock is owned by institutional investors.
About Elevation Oncology
(
Get Free ReportElevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.
See Also
Before you consider Elevation Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevation Oncology wasn't on the list.
While Elevation Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
